ProAmpac Celebrates Trio of Honors at 2024 AmeriStar Awards
ProAmpac, a leader in flexible packaging and material science, is thrilled to announce its recognition at the 2024 AmeriStar Awards, securing two wins in the Sustainable Packaging category and contributing to a third recognition for an innovative e-commerce solution. The accolades showcase ProAmpac's dedication to sustainability and innovation with the RAP Sandwich Wedge for Sammi's; ProActive Recyclable RP-1000 Paper Series for Marks & Spencer's organic potatoes; and the insulated paper bag known as ProActive Recyclable FiberCool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905477309/en/
Sammi's RAP Sandwich Wedge (Photo: Business Wire)
"The recognition by AmeriStar reflects our relentless pursuit of innovative and sustainable packaging solutions," said Chad Murdock, president of the fiber division at ProAmpac. "We're honored to have our efforts acknowledged, especially as we continue to advance in areas like the fiberization of packaging that contribute to a more circular economy."
Developed for Sammi’s grab-and-go sandwiches, the high-barrier RAP Sandwich Wedge, with a premium shelf appearance, utilizes a fiber-based carton board with a transparent window. This innovative solution employs modified atmosphere packaging, optimizing product preservation and visibility while maintaining very low oxygen levels for extended shelf life and decreased food waste.
Designed for Marks & Spencer’s organic potatoes, ProAmpac’s second award-winning innovation, the ProActive Recyclable® RP-1000 Paper Series, offers superior robustness and a premium natural look for packing organic potatoes. This fully recyclable packaging has premium sealant technology for running at rate on high-speed form-fill-seal equipment and is curbside recyclable in the UK, while also being FSC-certified for responsible sourcing.
"Our technical team is at the forefront of fiber packaging innovation across diverse markets," said Lynsey Maddison, director of product development at ProAmpac. "We are committed to advancing these technologies to help our customers achieve more sustainable packaging solutions. As we continue to explore new applications and improvements, our goal remains to drive impactful, eco-friendly advancements in the industry.”
In addition to these two awards, ProAmpac contributed to a win in the Packaging that Saves Food category with the ProActive Recyclable FiberCool, an insulated paper bag for e-commerce delivery. This fiber-based, curbside-recyclable solution replaces a bulky traditional multi-package system, reducing packaging weight and drastically enhancing thermal retention. “Our work on FiberCool exemplifies how we can innovate to meet the growing demand for sustainable packaging without compromising on performance,” said Ray Recchia, global innovation manager at ProAmpac. “By improving thermal insulation, we help reduce food spoilage and waste, giving customers more flexibility with their groceries after delivery,” adds Recchia.
As ProAmpac continues to innovate, it remains dedicated to enhancing sustainability and product performance. For more information on ProAmpac’s award-winning packaging solutions, visit ProAmpac.com or contact Marketing@ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905477309/en/
Contacts
Whitney Miles
Whitney Miles
ProAmpac
(617) 721-7040
Whitney.Miles@ProAmpac.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom